Lenalidomide Dossier ready for out-licensing
Midas Pharma has developed together with its development partner Grindeks JSC a fully compliant EU-CTD dossier for Lenalidomide (2,5/5/7,5/10/15/20/25 mg) which is ready for out-licensing!
First Marketing Authorizations based on our dossier have been granted in European countries.
The fact that the manufacturing site for the product is located in Latvia, being a white spot country, allows for day 1 launches upon SPC-expiry in June 2022.
We offer attractive and competitive prices along with small volumes per SKU.
Midas/Grindeks have filed different patent applications for Lenalidomide. We expect that most generic product developments that may be marketed from June 2022 onwards to bear a considerable risk of infringing our patents.
For further information please contact us.